SRX246

SRX246 is a potent, CNS-penetrant, highly selective, orally bioavailable Vasotocin 1a (V1a) receptor antagonist ( K i =0.3 nM for human V1a). SRX246 has no interaction at V1b and V2 receptors. SRX246 also displays negligible binding at 64 others receptors classes, including 35 G-proteincoupled receptors. SRX246 can be used for treatment of stress-related disorders In Vivo SRX246 (2 mg/kg; i.v.) treatment shows that the C max , AUC 0-∞ and t 1/2 values are 953 ng/mL, 1141 ng ▪h/mL, and 6.02 hours, respectively, in plasma pharmacokinetics. Following an oral administration (dose 20 mg/kg), The C max , AUC 0-∞ and t 1/2 values are 98.4 ng/mL, 624 ng ▪h/mL and 2.38 hours, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats Dosage: 2 mg/kg (20 mg/kg for p.o.) Administration: i.v. (Pharmacokinetic Analysis) Result: Following i.v. administration, the plasma concentration declined steadily with a half-life (t 1/2 ) of 6 hours. The C max and AUC 0-∞ values are 953 ng/mL, 1141 ng ▪h/mL, 6.02 hours. Following an oral administration, the C max , AUC 0-∞ and t 1/2 values 98.4 ng/mL, 624 ng ▪h/mL and 2.38 hours, respectively. Form:Solid IC50& Target:Ki: 0.3 nM (human Vasotocin 1a receptor)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet